VEA
SYRE icon

Virtus ETF Advisers’s Spyre Therapeutics SYRE Stock Holding History

Virtus ETF Advisers’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,972
Closed -$69.2K – 759
2024
Q4 		$69.2K Buy
2,972
+124
+4% +$3.64K 0.03% 382
2024
Q3 		$83.8K Buy
2,848
+51
+2% +$1.42K 0.04% 407
2024
Q2 		$65.8K Sell
2,797
-3,041
-52% -$103K 0.03% 438
2024
Q1 		$221K Sell
5,838
-401
-6% -$11.6K 0.12% 236
2023
Q4 		$134K Buy
+6,239
New +$86K 0.09% 317

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Virtus ETF Advisers's SYRE Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Spyre Therapeutics (SYRE) in Q1 2025, closing a stake of 2,972 shares — an estimated $69.2K sold.

Virtus ETF Advisers first reported a position in SYRE in Q4 2023 and held it in 5 quarters. The position peaked at $221K in Q1 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Spyre Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,972 Spyre Therapeutics shares in Q1 2025, an estimated $69.2K.
  • Virtus ETF Advisers first reported a position in Spyre Therapeutics in Q4 2023 and held it in 5 quarters.
  • Virtus ETF Advisers's Spyre Therapeutics position peaked at $221K in Q1 2024.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.